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Abstract
Background: Neurotrophins are growth factors that regulate cell growth, differentiation and apoptosis in the nervous
system. Their diverse actions are mediated through two different transmembrane – receptor signaling systems: Trk
receptor tyrosine kinases (TrkA, TrkB, TrkC) and p75NTR neurotrophin receptor. Trk receptors promote cell survival
and differentiation while p75NTR induces, in most cases, the activity of JNK-p53-Bax apoptosis pathway or suppresses
intracellular survival signaling cascades. Robust Trk activation blocks p75NTR -induced apoptosis by suppressing the JNK-
p53-Bax pathway. The aim of this exploratory study was to investigate the expression levels of neurotrophin receptors,
Trks and p75NTR, and the activation of JNK pathway in human astrocytomas and in adjacent non-neoplastic brain tissue.
Methods: Formalin-fixed paraffin-embedded serial sections from 33 supratentorial astrocytomas (5 diffuse fibrillary
astrocytomas, WHO grade II; 6 anaplastic astrocytomas, WHO grade III; 22 glioblastomas multiforme, WHO grade IV)
were immunostained following microwave pretreatment. Polyclonal antibodies against TrkA, TrkB, TrkC and
monoclonal antibodies against p75NTR and phosphorylated forms of JNK (pJNK) and c-Jun (pc-Jun) were used. The
labeling index (LI), defined as the percentage of positive (labeled) cells out of the total number of tumor cells counted,
was determined.
Results: Moderate to strong, granular cytoplasmic immunoreactivity for TrkA, TrkB and TrkC receptors was detected
in greater than or equal to 10% of tumor cells in the majority of tumors independently of grade; on the contrary, p75NTR
receptor expression was found in a small percentage of tumor cells (~1%) in some tumors. The endothelium of tumor
capillaries showed conspicuous immunoreactivity for TrkB receptor. Trk immunoreactivity seemed to be localized in
some neurons and astrocytes in non-neoplastic tissue. Phosphorylated forms of JNK (pJNK) and c-Jun (pc-Jun) were
significantly co-expressed in a tumor grade-dependent manner (p < 0.05). Interestingly, a statistically significant (p < 0.05)
reverse relationship between Trk receptors LIs and pc-Jun/pJNK LIs was noted in some glioblastomas multiforme.
Conclusion: In the context of astrocytomas, Trk receptors (TrkA, TrkB, TrkC) expression may promote tumor growth
independently of grade. Furthermore, activation of JNK pathway may contribute to progression towards malignancy.
Considering the fact that regional tumor heterogeneity may be a limiting factor for immunohistochemical studies, the
significance of the reverse relationship between Trk receptors and pc-Jun/pJNK LIs with respect to biological behavior
of human astrocytomas requires further evaluation.
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Background
Neurotrophins, a family of highly conserved polypeptide
growth factors [nerve growth factor (NGF), brain derived
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and
neurotrophin 4/5 (NT-4/5)] play a crucial role in function
of developing and adult vertebrate nervous system [1-3].
These growth factors mediate their actions through activa-
tion of two different transmembrane – receptor signaling
systems: the Trk receptor tyrosine kinases (TrkA, TrkB,
TrkC) and the p75NTR neurotrophin receptor, a member of
tumor necrosis factor (TNF) receptor superfamily [3,4].
Trk receptors promote cell survival via several intracellular
signaling cascades e.g. Ras/PI-3k/Akt pathway [1-4]. In
most cases, p75NTR functions as a ligand-stimulated apop-
totic receptor inducing the activity of the JNK-p53-Bax
pathway or suppressing Ras/PI-3k/Akt activation. Robust
Trk activation blocks p75NTR -induced apoptosis by sup-
pressing the JNK-p53-Bax pathway [3,4]. Recent data
reveal that precursor forms of some neurotrophins (pro-
neurotrophins) have the capacity to bind with high affin-
ity to p75NTR but not to Trk receptors suggesting that pro-
neurotrophins can elicit apoptosis via p75NTR even in cells
expressing survival-promoting Trk receptors [5-8].
The major downstream target of JNK [c-Jun N-terminal
kinases (JNKs)/Stress-activated protein kinases (SAPKs)
MAP kinases] is the c-Jun transcription factor which is
phosphorylated at serine residues 63 and 73 [9]. The axis
JNK/c-Jun is considered to play a crucial role in signal
transduction in the mammalian brain [10] while constitu-
tive activation of JNK pathway has been linked with glial
tumor development and progression [11].
Gliomas of astrocytic origin are the most common pri-
mary brain tumors of adults [12]. Astrocytomas accumu-
late genetic lesions affecting signal transduction pathways
that control cell survival and differentiation [13]. These
pathways are known to be implicated in the signaling cas-
cades of neurotrophins via their receptors Trks and p75NTR
[14]. The aberrant expression or mutations of the genes
encoding these receptors has been associated with glio-
mas [15-18] as well as medulloblastomas and neuroblas-
tomas [15,19-21]. Recently, tyrosine kinase inhibitors
(TKIs) have been designed to selectively inhibit the
growth of gliomas [22,23].
The aim of this study was to investigate immunohisto-
chemicaly the expression levels of neurotrophin receptors
TrkA, TrkB, TrkC, p75NTR and phosphorylated forms of
JNK (pJNK) and c-Jun (pc-Jun) in serial sections of human
astrocytomas of different grade of malignancy.
Methods
Tissue samples
Astrocytic gliomas (n = 33) were obtained from patients
who had undergone surgery at Department of Neurosur-
gery of the Patras University Hospital (Patras, Greece)
from 1991 to 1996. The formalin-fixed, paraffin-embed-
ded archival tissue blocks were retrieved, and the match-
ing hematoxylin and eosin (H & E) – stained slides were
reviewed and screened for representative tumor regions by
a neuropathologist. Tumors were evaluated by routine
methods for histopathology including immunohisto-
chemical staining for glial fibrillary acidic protein (GFAP)
and Ki-67 index as proliferation marker and graded
according to the diagnostic criteria of the WHO classifica-
tion system [12]. The tumor characteristics and clinical
features of the 33 patients are illustrated in Table 1.
Antibodies
Anti-pan-Trk (B-3) (dilution, 1:500), a mouse mono-
clonal antibody that reacts with a highly conserved car-
boxy terminus of TrkA gp140 and is reactive with TrkA,
TrkB, and TrkC receptors, anti-TrkA (763), a rabbit poly-
clonal antibody against a carboxy terminal epitope of
human TrkA (amino acids 763–777) (dilution, 1:100),
anti-TrkB (794) (dilution, 1:100), and anti-TrkC (798)
(dilution, 1:100), rabbit polyclonal antibodies against
carboxy terminal peptides (794–808 and 798–812 resi-
dues respectively) of gp145TrkB or gp145TrkC proteins
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibodies recognize the full-length isoforms
of Trk receptors and the catalytic intracellular tyrosine
kinase domain. According to the manufacturer, antibod-
ies do not cross react with each other. Anti-phospho-c-Jun
(KM-1) (dilution, 1:100), a mouse monoclonal antibody
which detects c-Jun only when it is phosphorylated on
Ser63 and anti-phospho-JNK (G-7) (dilution, 1:100), a
mouse monoclonal antibody directed against the carboxy
terminus of JNK1 phosphorylated on Thr183 and Tyr185
(identical to corresponding JNK2 sequence), were also
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). A mouse monoclonal anti-nerve growth factor recep-
tor (p75NGFR) antibody (dilution, 1:500) directed against
amino acids 1–160 of extracellular domain of p75NTR was
purchased from Lab Vision Corporation (Fermont, CA).
Immunohistochemistry
Immunohistochemical studies were performed on 4 µm
thick serial sections. A standard biotin-streptavidin perox-
idase procedure (StrAvigen MultiLink, Super Sensitive
Immunodetection System B-SA; Biogenex, San Ramon,
CA) for detection of pan-Trk, p75NTR, pc-Jun and pJNK
and an anti-mouse/rabbit poly HRP IHC Detection Sys-
tem (Chemicon International, Temecula, CA) for detec-
tion of TrkA, TrkB and TrkC were used according to
manufacturers' specifications. In brief, antigen retrievalBMC Cancer 2007, 7:202 http://www.biomedcentral.com/1471-2407/7/202
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was performed by placing the unstained slides in 0.01
mM citrate buffer (PH 6.0) and treating them in a micro-
wave oven for 10 min. Overnight incubation at 4°C was
performed for anti -pan-Trk, -p75NTR, -pc-Jun and -pJNK
primary antibodies and 1 hour at room temperature incu-
bation was performed for anti-TrkA, -TrkB and -TrkC pri-
mary antibodies. Antigen-antibody reaction was
visualized routinely using the peroxidase enhancer as a
chromogen. Mayer's hematoxylin nuclear staining was
used as a counter stain. Negative controls included unre-
lated primary antibodies. As positive controls, specimens
of inflammatory intestine known to express Trks and
p75NTR  [24] and glioblastoma specimens known to
express pc-Jun and pJNK [11] were used.
Analysis of staining and statistical methods
The results of immunohistochemical staining were evalu-
ated independently by two observers. Using a final mag-
nification of 400× (objective × eyepiece), ten non-
overlapping fields were chosen at random and a total of
100 tumor cells were counted manually in every field with
the aid of an ocular grid. To assess the fraction of immu-
nolabeled cells in each case and each antibody, the labe-
ling index (LI), defined as the percentage of positive
(labeled) cells out of the total number of tumor cells
counted, was determined. Labeled cells in tumor blood
vessels/microvascular proliferation were excluded from
the cell counts.
Nonparametric methods were used for the statistical anal-
ysis of the results. Spearman correlation was used to assess
significance of relationships between different LIs and
between age and LIs. Spearman correlation was also used
to assess significance of relationships between LIs and
grade. Wilcoxon rank test was used to compare LIs
between male and female. P values <0.05 were considered
significant. Statistical analyses were carried out using the
SPSS package (version 12.0).
Table 1: Trk receptors, pc-Jun and pJNK expression in human astrocytomas of different grade of malignancy.
Case Sex Age Histology/Grading Prior treatment pc-Jun pJNK panTrk TrkA TrkB TrkC
1 F 32 Diffuse fibrillary astrocytoma/II No 0 ND 70 ND 0 0
2 M 56 Diffuse fibrillary astrocytoma/II No 2 2 50 ND 30 60
3 F 38 Diffuse fibrillary astrocytoma/II No 0 0 0 0 0 0
4 M 24 Diffuse fibrillary astrocytoma/II No 10 10 10 10 5 5
5 M 11 Diffuse fibrillary astrocytoma/II No 2 2 70 50 ND ND
6 F 15 Anaplastic astrocytoma/III No 0 0 2 1 5 0
7 M 62 Anaplastic astrocytoma/III No 60 40 ND 50 60 40
8 M 56 Anaplastic astrocytoma/III No 0 0 20 10 1 ND
9 M 46 Anaplastic astrocytoma/III No 1 0 70 60 5 5
10 M 30 Anaplastic astrocytoma/III Yes 2 ND 5 ND ND ND
11 M 35 Anaplastic astrocytoma/III No 0 0 5 2 1 0
12 F 40 Glioblastoma multiforme/IV Yes 0 0 0 0 ND ND
13 M 19 Glioblastoma multiforme/IV No 10 10 30 60 30 0
14 M 65 Glioblastoma multiforme/IV No 90 90 20 ND 30 ND
15 F 57 Glioblastoma multiforme/IV No 50 50 10 ND ND ND
16 F 53 Glioblastoma multiforme/IV Yes 70 0 10 ND ND 0
17 M 67 Glioblastoma multiforme/IV No 70 0 1 1 0 0
18 F 60 Glioblastoma multiforme/IV Yes 10 10 50 ND ND 50
19 M 56 Glioblastoma multiforme/IV No 70 90 80 ND 80 80
20 F 44 Glioblastoma multiforme/IV No 0 90 ND 30 1 10
21 M 67 Glioblastoma multiforme/IV No 80 80 10 20 10 5
22 M 60 Glioblastoma multiforme/IV No 20 80 90 ND 60 75
23 F 59 Glioblastoma multiforme/IV No 70 70 80 ND 20 20
24 M 25 Glioblastoma multiforme/IV Yes 5 0 40 ND 10 10
25 F 66 Glioblastoma multiforme/IV No 90 40 60 60 30 10
26 M 61 Glioblastoma multiforme/IV No 25 10 90 ND 20 20
27 F 67 Glioblastoma multiforme/IV No 60 10 90 ND 60 5
28 M 42 Glioblastoma multiforme/IV No 0 0 70 70 ND ND
29 M 47 Glioblastoma multiforme/IV Yes 30 0 50 50 ND ND
30 F 65 Glioblastoma multiforme/IV No 50 70 90 ND 70 2
31 M 53 Glioblastoma multiforme/IV No 70 60 30 ND ND ND
32 F 55 Glioblastoma multiforme/IV No 60 40 30 ND 50 30
33 M 77 Glioblastoma multiforme/IV No 1 0 30 ND 0 0
ND: Not detected due to lack of serial sections.BMC Cancer 2007, 7:202 http://www.biomedcentral.com/1471-2407/7/202
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Results
Trk expression in astrocytomas
Moderate to strong Trk immunoreactivity was found in
the majority of astrocytomas included in this study. Trk
immunoreactivity was cytoplasmic with granular appear-
ance (Figures 1, 2). The majority of the tumors exhibited
areas with focally immunoreactive tumor cells, corre-
sponding to 1–90% of the cell population while other
areas were entirely immunonegative. The rest of the
tumors displayed scattered immunoreactive tumor cells.
In diffuse fibrillary astrocytomas (WHO; grade II) reactive
astrocytes showed strong immunoreactivity for all Trk
receptors. Regarding grade IV tumors (glioblastomas mul-
tiforme), Trk-positively stained cells had a tendency to
aggregate around tumor blood vessels or in the vicinity
bordering tumor necrosis. Elongated, bipolar cells as well
as giant cells (Figure 2) were intensely stained for all Trk
receptors. In the majority of tumors, in immunopositive
areas, the endothelium of tumor capillaries as well as
florid angioproliferative changes and/or proliferations of
smooth muscle cells showed conspicuous immunoreac-
tivity for TrkB receptor. In the apparently "normal tissue"
of peritumoral region found in some cases the Trk-immu-
noreactivity localized in some neurons and astrocytes.
Blood capillaries were non reactive.
There was no statistically significant correlation between
Trk expression and histological grade (Spearman correla-
tion of grade with panTrk = 0.22, p = 0.22, Spearman cor-
relation of grade with TrkA = 0.27, p = 0.30, Spearman
correlation of grade with TrkB = 0.40, p = 0.05, Spearman
correlation of grade with TrkC = 0.21, p = 0.31). Trk
expression was not significantly correlated with age
(Spearman correlation of age with panTrk = 0.27, p =
0.13, Spearman correlation of age with TrkA = 0.11, p =
0.66, Spearman correlation of age with TrkB = 0.25, p =
0.24, Spearman correlation of age with TrkC = 0.23, p =
0.27). Furthermore, Trk expression was not different by
gender (Wilcoxon test: p = 0.40 for panTrk, p = 0.27 for
TrkA, p = 0.52 for TrkB, p = 0.38 for TrkC).
p75NTR expression in astrocytomas
p75NTR immunoreactivity was confined to cytoplasm of a
small number (~1%) of scattered or small clusters of
tumor cells in a few tumors. Normal tissue was totally
p75NTR -negative.
Relationship between Trk and pc-Jun/pJNK expression
Trk receptors, pc-Jun and pJNK expression was analyzed
by examining adjacent (serial) sections of each specimen.
Only the nuclear immunoreactivity was evaluated for
both pc-Jun and pJNK proteins. There was a statistically
significant association between pc-Jun and pJNK expres-
sion (Spearman correlation = 0.57, p = 0.001). There was
also a statistically significant positive correlation between
pc-Jun/pJNK expression and grade of malignancy (Spear-
man correlation of pc-Jun with grade = 0.52, p = 0.002,
Spearman correlation of pJNK with grade = 0.36, p =
0.04). pc-Jun/pJNK expression was significantly correlated
with age (Spearman correlation of age with pc-Jun = 0.60,
p = 0.000, Spearman correlation of age with pJNK = 0.38,
p = 0.03). pc-Jun/pJNK expression was not different by
gender (Wilcoxon test: p = 0.89 for pc-Jun, p = 0.83 for
pJNK). Normal tissue was pc-Jun and pJNK imunonega-
tive. Regarding co-expression of Trk receptors and pc-Jun/
pJNK in the same tumor cells three patterns were noted:
Trk-positive – pc-Jun/pJNK-positive cells, Trk-positive –
TrkB (a) and TrkC (b) immunoexpression in homologous fields of immediately adjacent sections of diffuse fibrillary astrocy- toma (grade II) Figure 1
TrkB (a) and TrkC (b) immunoexpression in homologous fields of immediately adjacent sections of diffuse fibrillary astrocy-
toma (grade II). Note the cellular distribution of TrkC receptor in a morphologically indistinguishable cell (arrow) from the 
nearby cells, ×400.BMC Cancer 2007, 7:202 http://www.biomedcentral.com/1471-2407/7/202
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pc-Jun/pJNK-negative cells and Trk-negative – pc-Jun/
pJNK-positive cells (Figure 3, 4). Interestingly, TrkB
expression was significantly correlated with pc-Jun expres-
sion (Spearman correlation = 0.60, p = 0.002) and pJNK
expression (Spearman correlation = 0.63, p = 0.001). Fur-
thermore, TrkC expression was significantly correlated
with pJNK expression (Spearman correlation = 0.62, p =
0.002).
Some glioblastomas multiforme (gradeIV) showed a
reverse relationship between Trk and pc-Jun/pJNK LIs. In
other words, a high LI for Trk expression was associated
with a low LI for pc-Jun/pJNK expression in the same
tumor and vice versa (Table 1). In this subgroup of gliob-
lastomas multiforme (grade IV) a statistically significant
negative correlation between LIs for panTrk expression
and pc-Jun/pJNK was found (Spearman correlation of
panTrk with pc-Jun = -0.7, p = 0.01, Spearman correlation
of panTrk with pJNK = -0.7, p = 0.008).
Discussion
There is growing evidence relating neurotrophin receptors
expression in pathogenesis of astrocytomas. Wang et al.
(1998) have detected TrkA, TrkB and TrkC expression in
neoplastic astrocytes but not in neoplastic oligodendro-
cytes and suggested that Trk expression may be useful for
lineage marking but unrelated to any signaling cascade
involved in the maintenance of a transformed phenotype
[16]. On the other hand, Wadhwa et al. (2003) have
found a high TrkA and TrkB expression in low grade astro-
cytic tumors (grade I and grade II) and a down regulation
of both Trk receptors in high grade tumors (grade III and
grade IV) and concluded that these receptors may contrib-
ute to progression towards malignancy [17]. Recently,
Chiaretti et al. (2004) showed that there might be an asso-
ciation between neurotrophin receptors expression and
the pathobiology of childhood low-grade astrocytomas
(grade I and II) [18].
Recent data support that, in glial cells, neurotrophins,
through their Trk receptors, may act as mitogens in
response to injury [25] and promote cell growth in gliob-
lastoma cell lines [26]. Thus, the overexpression of Trk
receptors (independently of grade) found in astrocytomas
in the present study, may indicate an accelerated down-
stream tumor cell survival signaling pathway and suggests
a potential mechanism for malignant transformation
even in low grade astrocytomas.
In contrast to gliomas, tumors of neuroepithelial origin
such as medulloblastomas [19,20] and neuroblastomas
[21] which express Trk receptor have a favorable progno-
sis. It seems that neurotrophins may activate, through
their receptors, distinctly different signaling pathways in
cells of different lineages.
Trk receptors are often co-expressed with p75NTR and in
such instances pro-apoptotic responses of p75NTR e.g. acti-
vation of JNK pathway, are, in most cases, suppressed [4].
The absence of p75NTR neurotrophin receptor in astrocyto-
mas included in this study erases the possibility of apop-
tosis mediated by binding of pro-neurotrophins (pro-
NGF and/or pro-BDNF) to p75NTR, even in the presence of
survival-promoting Trk receptors [5-8], in these tumors.
However, JNK activation has been reported in human gli-
omas [11] and a grade-dependent expression of pc-Jun/
pJNK was detected in the present study. It is worth noting
that a reverse relationship between Trk and pc-Jun/pJNK
LIs was detected in some glioblastomas multiforme
(grade IV). It seems that glial cell survival may result from
a balance between positive and negative regulators (mod-
ulated by activation of selective signaling pathways
through tyrosine kinases and cytokines receptors). Previ-
ous data demonstrate also that cross talk between neuro-
trophin/Trk signal transduction axis and JNK pathway
play a specific role in glial cell migration [27]. Consider-
ing the fact that gliomas are widely infiltrating tumors,
future studies would elucidate the significance of the
above findings with respect to biological behavior of
human astrocytomas.
TrkB receptor expression detected in tumor vessels sug-
gests that these receptors may be an important compo-
nent of the angiogenic cascade required for the
development of astrocytic tumors in view of recent data
showing the neurotrophin-dependent proliferation of
brain capillary endothelial cells [28].
Finally, tumor cells acquire the ability to activate several
pathways in order to survive and neurotrophin/Trk signal
Strong TrkA granular cytoplasmic immunostaining in giant  cells of glioblastoma multiforme (grade IV), ×400 Figure 2
Strong TrkA granular cytoplasmic immunostaining in giant 
cells of glioblastoma multiforme (grade IV), ×400.BMC Cancer 2007, 7:202 http://www.biomedcentral.com/1471-2407/7/202
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transduction axis as well as JNK pathway may regulate
such survival possibilities. The complexity and cross talk
between different signaling cascades may limit the poten-
tial therapeutic efficacy of targeting a single molecule.
Therefore, it appears necessary to develop an expanded
molecular sub-classification of these tumors and to con-
sider combinatorial treatment regimens targeted at differ-
ent pathways. However, astrocytomas are strikingly
heterogeneous tumors in terms of protein profile even
within a single tumor which may be a limiting factor in
the immunohistochemical evaluation of protein expres-
sion levels in these tumors.
Conclusion
Trk (TrkA, TrkB, TrkC) receptor overexpression may pro-
mote tumor cell survival and enhance tumor growth while
p75NTR  mediated apoptosis has no functional role in
human astrocytomas. Activation of JNK pathway may
contribute to progression towards malignancy. Further
studies would elucidate the significance of the reverse
relationship between Trk LIs and pc-Jun/pJNK LIs. As
tumor cells activate several pathways in order to survive,
future therapeutic approach may consider combinatorial
treatment regimens targeted at different pathways.
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